Pemafibrate: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== Pemafibrate == | |||
[[File:Pemafibrate.svg|thumb|right|Chemical structure of Pemafibrate]] | |||
'''Pemafibrate''' is a novel [[fibrate]] drug that acts as a selective [[peroxisome proliferator-activated receptor]] (PPAR) alpha modulator. It is primarily used for the treatment of [[dyslipidemia]], particularly in reducing [[triglyceride]] levels and improving [[lipid profile]]s in patients with [[hyperlipidemia]]. | |||
Pemafibrate is used for the treatment of | |||
== | === Mechanism of Action === | ||
Pemafibrate functions by selectively modulating the activity of the PPAR-alpha receptor, which plays a crucial role in the regulation of [[lipid metabolism]]. By activating PPAR-alpha, pemafibrate enhances the oxidation of fatty acids and increases the catabolism of triglyceride-rich particles, leading to a reduction in plasma triglyceride levels. This mechanism also contributes to an increase in [[high-density lipoprotein]] (HDL) cholesterol levels. | |||
== | === Clinical Use === | ||
Pemafibrate | Pemafibrate is indicated for the treatment of hyperlipidemia, particularly in patients who have not achieved adequate control of their lipid levels through diet and lifestyle modifications alone. It is often prescribed to patients with [[hypertriglyceridemia]] to reduce the risk of [[cardiovascular disease]]. | ||
== | === Pharmacokinetics === | ||
Pemafibrate is administered orally and is well absorbed in the gastrointestinal tract. It undergoes hepatic metabolism and is primarily excreted in the urine. The drug has a favorable pharmacokinetic profile, with a long half-life that allows for once-daily dosing. | |||
=== Side Effects === | |||
Common side effects of pemafibrate include mild gastrointestinal disturbances, such as [[nausea]] and [[diarrhea]]. Some patients may experience [[muscle pain]] or [[myopathy]], although these effects are less common compared to other fibrates. Regular monitoring of liver function tests is recommended during treatment. | |||
=== Comparison with Other Fibrates === | |||
Compared to traditional fibrates like [[fenofibrate]] and [[gemfibrozil]], pemafibrate offers a more selective action on PPAR-alpha, which may result in a better safety profile and fewer drug interactions. Its selectivity also contributes to its efficacy in lowering triglyceride levels and improving HDL cholesterol. | |||
== Related Pages == | |||
* [[Fibrate]] | |||
* [[Peroxisome proliferator-activated receptor]] | |||
* [[Hyperlipidemia]] | * [[Hyperlipidemia]] | ||
* [[ | * [[Triglyceride]] | ||
* [[ | * [[High-density lipoprotein]] | ||
[[Category:Hypolipidemic agents]] | |||
[[Category:PPAR agonists]] | |||
Latest revision as of 03:40, 13 February 2025
Pemafibrate[edit]
Pemafibrate is a novel fibrate drug that acts as a selective peroxisome proliferator-activated receptor (PPAR) alpha modulator. It is primarily used for the treatment of dyslipidemia, particularly in reducing triglyceride levels and improving lipid profiles in patients with hyperlipidemia.
Mechanism of Action[edit]
Pemafibrate functions by selectively modulating the activity of the PPAR-alpha receptor, which plays a crucial role in the regulation of lipid metabolism. By activating PPAR-alpha, pemafibrate enhances the oxidation of fatty acids and increases the catabolism of triglyceride-rich particles, leading to a reduction in plasma triglyceride levels. This mechanism also contributes to an increase in high-density lipoprotein (HDL) cholesterol levels.
Clinical Use[edit]
Pemafibrate is indicated for the treatment of hyperlipidemia, particularly in patients who have not achieved adequate control of their lipid levels through diet and lifestyle modifications alone. It is often prescribed to patients with hypertriglyceridemia to reduce the risk of cardiovascular disease.
Pharmacokinetics[edit]
Pemafibrate is administered orally and is well absorbed in the gastrointestinal tract. It undergoes hepatic metabolism and is primarily excreted in the urine. The drug has a favorable pharmacokinetic profile, with a long half-life that allows for once-daily dosing.
Side Effects[edit]
Common side effects of pemafibrate include mild gastrointestinal disturbances, such as nausea and diarrhea. Some patients may experience muscle pain or myopathy, although these effects are less common compared to other fibrates. Regular monitoring of liver function tests is recommended during treatment.
Comparison with Other Fibrates[edit]
Compared to traditional fibrates like fenofibrate and gemfibrozil, pemafibrate offers a more selective action on PPAR-alpha, which may result in a better safety profile and fewer drug interactions. Its selectivity also contributes to its efficacy in lowering triglyceride levels and improving HDL cholesterol.
